Primary Outcome Measures:
Change in number of terminal hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of terminal hair follicles over the treatment period.
Change in number of anagen hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of anagen hair follicles over the treatment period.
Change in number of telogen hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of telogen hair follicles over the treatment period.
Change in number of catagen hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of catagen hair follicles over the treatment period.
Change in number of vellus (vellus-like) miniaturized hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of vellus (vellus-like) miniaturized hair follicles over the treatment period.
Change in number of indeterminate hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of indeterminate hair follicles over the treatment period.